Emerald Logic announces collaboration with King's College London on quantitative biomarker discovery
ALISO VIEJO, Calif., Feb. 6, 2013 /PRNewswire-iReach/ -- King's College London and Emerald Logic, a pioneer in quantitative personalized medicine, have established an ongoing collaboration to identify blood markers for Alzheimer's and other neurological conditions, and to produce screening classifiers by integrating biomarkers with other diagnostic modalities.
The two organizations have already completed ground-breaking work together, identifying 14 discriminative blood markers from a set of over 11,000 markers on 245 study subjects, validated on an additional 82 subjects in two separate hold-out samples. Using these markers, plus APOE genetic information and demographics, the collaborators produced a mathematical classifier of 94% accuracy in distinguishing Alzheimer's study subjects from controls or with those with mild cognitive impairment. The biomarker identification and classifier production were completed in six weeks.
Alzheimer's disease affects 1 in 8 people over the age of 65. Today, there are over 36 million people diagnosed with Alzheimer's worldwide, and equally as many family members spend much of their time caring for these patients.
The key collaborators from King's College London are Simon Lovestone and Richard Dobson. Dr. Lovestone is Professor of Old Age Psychiatry at the Institute of Psychiatry (IoP), King's College London, Director of Research at King's Health Partners, and Director of the National Institute for Health Research Biomedical Research Centre (NIHR BRC) for Mental Health at the South London and Maudsley NHS Foundation Trust (SLAM) and King's College London. Dr. Dobson is Bioinformatics Lecturer at the NIHR BRC for Mental Health at SLAM and King's and at the IoP at King's.
Professor Lovestone says: "Emerald Logic's software evolved Alzheimer's disease classifiers from our blood markers with the best accuracy we've seen to date, while simultaneously identifying the most useful markers from a vast dataset including a whole genome transcript assay."
Patrick Lilley, CEO of Emerald Logic, says: "It's a privilege to work on one of the most important diseases of this century with people of Dr. Lovestone's and Dr. Dobson's caliber. Their expertise, rigorous approach to data quality, and groundbreaking research were essential to our FACET software evolving accurate and robust Alzheimer's classifiers."
The collaboration of King's College London and Emerald Logic is intended to have a translational focus – bringing insight and practical tools to the detection and potential treatment of Alzheimer's and other diseases of aging.
About King's College London:
King's College London is one of the top 30 universities in the world (2012/13 QS international world rankings), and was The Sunday Times 'University of the Year 2010/11', and the fourth oldest in England. A research-led university based in the heart of London, King's has more than 24,000 students (of whom more than 10,000 are graduate students) from nearly 140 countries, and more than 6,100 employees. King's is in the second phase of a £1 billion redevelopment programme which is transforming its estate.
King's has an outstanding reputation for providing world-class teaching and cutting-edge research. In the 2008 Research Assessment Exercise for British universities, 23 departments were ranked in the top quartile of British universities; over half of our academic staff work in departments that are in the top 10 per cent in the UK in their field and can thus be classed as world leading. The College is in the top seven UK universities for research earnings and has an overall annual income of nearly £525 million (year ending 31 July 2011).
King's has a particularly distinguished reputation in the humanities, law, the sciences (including a wide range of health areas such as psychiatry, medicine, nursing and dentistry) and social sciences including international affairs. It has played a major role in many of the advances that have shaped modern life, such as the discovery of the structure of DNA and research that led to the development of radio, television, mobile phones and radar.
King's College London and Guy's and St Thomas', King's College Hospital and South London and Maudsley NHS Foundation Trusts are part of King's Health Partners. King's Health Partners Academic Health Sciences Centre (AHSC) is a pioneering global collaboration between one of the world's leading research-led universities and three of London's most successful NHS Foundation Trusts, including leading teaching hospitals and comprehensive mental health services. For more information, visit: www.kingshealthpartners.org.
The College is in the midst of a five-year, £500 million fundraising campaign – World questions|King's answers – created to address some of the most pressing challenges facing humanity as quickly as feasible. The campaign's five priority areas are neuroscience and mental health, leadership and society, cancer, global power and children's health. More information about the campaign is available at www.kcl.ac.uk/kingsanswers.
About Emerald Logic:
Emerald Logic is a pioneer in quantitative personalized medicine and biomarker discovery. The company's FACET (FAst Collective Evolution Technology) software combines principles and math from biology, engineering, and particle physics to answer intractable questions with high human and economic impact. The company is based in California.
Patrick Lilley, Emerald Logic, (714) 225-1561, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Emerald Logic